Femme et Homme
- | Pays :
- France
- | Organes : -
- | Spécialités : -
Extrait
This is a Phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of escitalopram (30 mg/day) in two parallel groups (randomization ratio, escitalopram 2/placebo 1).
Critère d'inclusion
- pulmonary hypertension